Drug Database
US

ustekinumab (Qoyvolma)

✓ Approved

Celltrion, Inc. · IL12B · Monoclonal Antibodies

What is ustekinumab?

ustekinumab is a monoclonal antibodies developed by Celltrion, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesQoyvolma
CompanyCelltrion, Inc.
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetIL12B, IL23A
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Celltrion, Inc.

Mechanism of Action

Molecular Targets

ustekinumab acts on 2 molecular targets:

IL12Binterleukin 12B (CLMF2, CLMF)
IL23Ainterleukin 23 subunit alpha (P19, SGRF)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

ustekinumab is developed for 4 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersPsoriatic arthropathy✓ Approved

Related Research Articles

PubMedBiological procedures online2026-11-12

Engineering SIM-1 and MZ-1 PROTACs for enhanced target degradation in KSHV-infected immortalized endothelial cells.

Chen Jungang J, Wang Zhengyu Z, Karmoker Jarna J, Fan Jiaojiao J et al.

Kaposi's Sarcoma-associated Herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi's Sarcoma (KS), which are still lacking of treatment options. Members of the bromodomain and extra-terminal domain (BET) family, especially bromodomain-containing protein 4 (BRD4), play important roles in RNA polymerase II-mediated transcriptional regulation and are required for the expression of many tumor-driving oncogenes in various cancer cells. Therefore, BET proteins have become attractive targets for anticancer drug development. Our recent studies showed that KSHV-infected immortalized endothelial cells displayed strong resistance to BET inhibitors such as (+)-JQ1. In contrast, we found out MZ-1 and SIM-1, two of BRD4 PROTAC degraders, as effective inhibitors of cell growth in these cells. To develop PROTAC molecules with enhanced BRD4 degradation potency, we introduced an (S)-methyl group at the benzylic position of the VHL ligand in the VHL-based BRD4 PROTACs MZ-1 and SIM-1, thereby designing and generating MZ-1-ME and SIM-1-ME, respectively. In KS cellular model, MZ-1-ME and SIM-1-ME exhibited enhanced BRD4 degradation and anticancer activities compared with their parental compounds, which may represent promising PROTACs for development of BRD4-targeted therapies against KS.

PMID 43015613
Read full article →
PubMedJournal of medicinal chemistry2026-11-12

Discovery of Novel Quinazoline-Based KDM1A Inhibitors as Dual Inducers of Ferroptosis and Apoptosis in Esophageal Cancer.

Zhao Li-Juan LJ, Yu Rui R, Liu Ying Y, Yin Jia-Yi JY et al.

Lysine-specific demethylase 1 (KDM1A) is an FAD-dependent epigenetic target implicated in cancer progression. Starting from lead compound ZY-1 (IC50 = 105 nM), we designed a series of quinazoline-based reversible KDM1A inhibitors via a functional group migration strategy. Structure-activity relationship studies (SARs) identified JH-1 as the most potent analogue, with an IC50 of 35 nM. JH-1 selectively binds KDM1A, inhibits H3K4me1/2 demethylation, and induces both ferroptosis (lipid ROS accumulation) and apoptosis in esophageal cancer cells. In a KYSE510 xenograft model, oral administration of JH-1 significantly suppressed tumor growth without obvious toxicity. These results establish JH-1 as a promising reversible KDM1A inhibitor and validate the quinazoline scaffold for epigenetic cancer therapy.

PMID 43018546
Read full article →
PubMedCritical care medicine2026-11-12

National Early Warning Score 2-Guided Sepsis Hour-1 Bundle Care for Adults With Suspected Sepsis in the Emergency Department: A Hybrid Type 1 Effectiveness-Implementation Stepped-Wedge Randomized Controlled Trial Pilot Study (NEWS-1 TRIPS).

Lam Rex Pui Kin RPK, Hung Kevin Kei Ching KKC, Lui Chun Tat CT, Kwok David Wai Shing DWS et al.

To increase the uptake of the Surviving Sepsis Campaign Hour-1 Bundle, we implemented a novel sepsis care model (National Early Warning Score [NEWS]-1 care), in which the Hour-1 Bundle is objectively triggered by a high NEWS-2 (≥ 5). We aimed to determine the feasibility of a full-scale type 1 hybrid effectiveness-implementation trial of this model. A pilot type 1 hybrid trial, comprising a stepped-wedge cluster randomized controlled trial and mixed-methods implementation evaluation with staff focus group interviews and an anonymous survey guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework. Four emergency departments in Hong Kong. Adult patients of 18 years or older with a clinical diagnosis of infection requiring hospitalization and a NEWS-2 greater than or equal to 5. Implementation of the Hour-1 Bundle when NEWS-2 was greater than or equal to 5. The primary outcome was the feasibility of a full-scale hybrid trial, evaluated based on 14 progression criteria. Preliminary clinical effectiveness and safety were assessed, alongside implementation barriers and facilitators. During the implementation phase, compliance with lactate, blood culture, and antibiotics increased significantly. All progression criteria were met, except for suboptimal overall bundle compliance (56.1%). Exploratory intention-to-treat analysis (standard care group, n = 102; NEWS-1 group, n = 98) showed no significant between-group difference in 30-day all-cause mortality (standard care group, 3.9%; NEWS-1 group, 9.2%; absolute risk difference, 5.3%; 95% CI -1.6% to 12.1%); in-hospital, 90-day all-cause, or sepsis-related mortality; need for mechanical ventilation, renal replacement therapy, intensive care, or surgery; or ventilator-free days and adverse events. Implementation evaluation identified 15 barriers and 13 facilitators. The effectiveness of NEWS-1 care remained uncertain, though adverse events were rare. A full-scale hybrid stepped-wedge trial is feasible but requires a much larger sample size. Real-world implementation barriers and facilitators should be considered in sepsis management guidelines.

PMID 43018426
Read full article →
PubMedFrontiers in plant science2026-11-12

Nitrogen management in rainfed castor: a comprehensive analysis of productivity, nutrient use efficiency, economics, energy flow, and carbon footprint.

Mohan Kumar Revappa R, Madival Yamanura Y, Paramesha Venkatesh V, Jadesha Ganiga G et al.

Nitrogen (N), an essential plant nutrient characterized by the lowest use efficiency and multiple loss pathways, challenges its management in rainfed castor. Therefore, a field experiment was conducted over three consecutive Kharif seasons (2022-2024) to develop an adoptable N management strategy for rainfed castor cultivation. The study investigated the impact of eight N management modules viz., Recommended rate of fertilizer (RRF) (40-40-25 kg N-P2O5-K2O ha-1), 50% recommended rate of basal N (RRBN) +2 ml l-1 Nano Urea at 30 and 60 days after sowing (DAS), 50% RRBN + 2% Urea spray at 30 and 60 DAS, 75% RRBN + 2 ml l-1 Nano Urea at 30 and 60 DAS, 75% RRBN + 2% Urea spray at 30 and 60 DAS, 100% RRBN + 2 ml l-1 Nano Urea at 30 and 60 DAS, 100% RRBN + 2% Urea spray at 30 and 60 DAS, and recommended rate of phosphorous and potassium (RRPK) (00-40-25 kg N-P2O5-K2O ha-1) and were arranged in randomized complete block design with three replications. The study found that the combined soil and foliar application of N had a promising effect on crop productivity than soil-only N application. Aqueous solution of urea (2%) proved effective than Nano-Urea (2 ml L-1) for foliar fertilization of N. Specifically, application of 100% RRBN through soil (20 kg ha-1), followed by foliar sprays of 2% Urea at 30 and 60 DAS, improved growth and yield traits of castor. Consequently, it produced significantly higher seed yield (1546 kg ha-1), oil content (42.7%), and N uptake in castor (34.9 kg ha-1). Due to inverse relationship, N substituted via foliar fertilization enhanced the partial factor productivity (67.8-106 kg kg-1) compared to soil-only N application (32.5 kg kg-1). Foliar fertilization depletes the soil N pool as observed through +ve N balance index (10.7-12.1). Furthermore, 100% RRBN + foliar sprays of 2% Urea at 30 and 60 DAS found to be remunerative, besides enhancing energy (58,726 MJ ha-1), carbon (C) output (1,947 kg-CE ha-1), net energy and C-gain. These findings highlight that partial N substitution through foliar applications optimizes castor productivity, economics, energy, and environmental security in rainfed castor.

PMID 43016720
Read full article →
PubMedVeterinarni medicina2026-11-12

Impact of preanalytical sample handling on GLP-1 measurement in porcine plasma: A pilot ELISA-based study.

Culka Lubomir L, Novotny Jaroslav J, Leskova Lenka L, Krepelkova Zuzana Z et al.

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that plays a key role in the regulation of glucose metabolism; however, it is highly sensitive to biological sample handling conditions. The aim of this pilot study, conducted in two piglets and two adult finishing pigs, was to compare the effects of selected preanalytical factors on measured GLP-1 concentrations in porcine plasma and to identify conditions suitable for its reliable determination using ELISA. The evaluated factors included blood collection tube type (EDTA vs EDTA with a DPP-4 inhibitor), centrifugation temperature (4 °C vs room temperature), and sample processing conditions (fresh vs frozen samples). In addition, the influence of the physiological status of the animals (fasting vs post-glucose administration) was assessed. Samples collected in tubes containing a DPP-4 inhibitor showed higher measured GLP-1 concentrations than standard EDTA samples. Samples processed at room temperature showed higher GLP-1 concentrations compared to samples centrifuged at 4 °C. The obtained results suggest that sample handling conditions may significantly influence GLP-1 determination by ELISA. The use of EDTA tubes containing a DPP-4 inhibitor combined with rapid sample processing and centrifugation at 4 °C may represent a suitable procedure for standardised GLP-1 measurement.

PMID 43017084
Read full article →
PubMedInfection and immunity2026-11-12

Hyperglycemia promotes maladaptive Dectin-1 signaling and impairs skin antifungal host defense.

Reyna Dante E DE, Davis Erin E, Salina Ana C G ACG, Blackman Amondrea A et al.

People with chronic hyperglycemia are more susceptible to fungal skin infections, yet the mechanisms behind worse clinical outcomes remain unclear. Using both in vivo and in vitro models, we explored how hyperglycemia affects skin antifungal defenses. Hyperglycemic mice showed increased susceptibility to Candida albicans skin infections, with larger lesions and higher fungal loads at all time points tested. Histology revealed larger abscesses, more extensive myeloid cell infiltration, and poorer control of fungal invasion, all associated with increased chemoattractant production on day 1 post-infection. Glucose reduction with the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide reduced lesion size and fungal burden in infected diabetic mice, linking metabolic control to the restoration of innate immune function. Phagocytes and keratinocytes exposed to high glucose exhibited inhibited fungal ingestion. RNA-seq analysis of C. albicans-infected dermal macrophages cultured under high-glucose conditions showed enrichment of genes related to the C-type lectin receptor pathway, including Clec7a (Dectin-1), and also revealed inhibition of downstream signaling pathways required for effective phagocytosis. Pharmacologic blockade or genetic deletion of Dectin-1 restored fungal uptake under high-glucose conditions and improved host defense in vivo. Dectin-1 signaling in hyperglycemia increased prostaglandin E2 (PGE2) production along with increased abundance of microsomal prostaglandin E synthase-1 (mPGES-1). Inhibition of PGE2 synthesis rescued deficient phagocytic function. These findings identify maladaptive innate immune sensing as a key mechanism underlying susceptibility to fungal infection in diabetes and reveal how metabolic stress converts antifungal recognition pathways into drivers of inflammatory dysfunction.

PMID 43018239
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ustekinumab